# Structure and Mechanisms of Lysine Methylation Recognition by the Chromodomain in Gene Transcription

Kyoko L. Yap and Ming-Ming Zhou*

Department of Structural and Chemical Biology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1677, New York, New York 10065, United States

ABSTRACT: Histone methylation recognition is accomplished by a number of evolutionarily conserved protein domains, including those belonging to the methylated lysine-binding Royal family of structural folds. One well-known member of the Royal family, the chromodomain, is found in the HP1/chromobox and CHD subfamilies of proteins, in addition to a small number of other proteins that are involved in chromatin remodeling and gene transcriptional silencing. Here we discuss the structure and function of the chromodomain within these proteins as methylated histone lysine binders and how the functions of these chromodomains can be modulated by additional post-translational modifications or binding to nucleic acids.

At the heart of epigenetic transcriptional regulation is the recognition of chromatin in active or repressed states by proteins that directly or indirectly affect changes during transcription. Whether chromatin is in an active or repressed state is reflected by the covalent modifications found on the tails and cores of the DNA-packing histones. The deposition or removal of these modifications coincides with gene transcriptional activation or silencing. In recent years, a number of evolutionarily conserved domains have been identified that interact with specific histone modifications associated with a particular transcriptional state. Furthermore, many of these protein domains are capable of recognizing multiple levels of valency (e.g., unmodified and mono-, di-, and trimethylation). Proteins often contain tandem repeat domains or multiple domains that have distinct, specialized histone recognition modes. Two adjacent domains in combination may be required to recognize a single histone modification, typically with one domain recognizing the modification and the other binding neighboring residues in the histone sequence. Single domains have also been shown to recognize two proximal modifications on the same histone tail. Although structural studies have yet to show tandem domain recognition of multiple modifications, it is believed that this could be possible and that these modifications may occur on trans histone tails. Therefore, recognition of combinatorial modifications offers a mechanism by which gene transcription can be controlled in a subtly complex manner.[1]

Chromodomains[2] are methylated histone lysine recognition modules that belong to a larger, structurally related family of protein domains termed the Royal family.[3] The Royal family includes Tudor, chromo, malignant brain tumor (MBT), PWWP, and Agenet domains and has descended from a common ancestral fold with an evolutionarily conserved ability to recognize methylated ligands. The basic fold of these Royal domains includes a curved three-stranded β-sheet and an adjacent helix; for the non-chromodomain Royal folds, additional strands help form a β-barrel structure sometimes called a Tudor barrel. The methylated ligand is coordinated by two, three, or four well-conserved aromatic residues that form a "cage" around the moiety. A detailed summary of the different folds involved in methylated histone lysine (and other histone modification) recognition has been covered by a recent structure-based review.[1] Here, we will describe recent advancements in our understanding of the structure and function of chromodomains in transcriptional regulation.

■ CHROMODOMAINS ARE FOUND IN A RELATIVELY SMALL AND SPECIFIC GROUP OF PROTEINS

The number of proteins that contain chromodomains within the human genome is surprisingly low given the complexity of site- and state-specific histone lysine methylation in gene transcription, and as compared to that of the acetyllysine binding bromodomain family in humans.[4] A phylogenetic tree (Figure 1A) generated by a sequence-based alignment of all known chromodomains in the human genome and a minor structural variant, the chromo barrel domain (Figure 1B), suggests that subfamily classification may provide clues about the functions of these domains within encompassing proteins. We propose three separate subfamilies: the heterochromatin protein 1 (HP1)/chromobox (CBX) subfamily, the chromodomain helicase-DNA-binding (CHD) subfamily, and the chromo barrel domain family. The chromodomains of HP1 and the CBX homologues of *Drosophila* Polycomb (Pc) are highly related and thus are believed to have arisen from a common

Figure 1. Chromodomains and chromo barrel domains in the human genome. (A) Unrooted phylogenetic tree of chromodomains and chromo barrel domains (green). (B) Alignment of sequences used to generate the tree in panel A. Residue numbers of first and last amino acids in the alignment are noted. Secondary structure elements (orange for α-helices and cyan for β-strands) defined for HP1β [from Protein Data Bank (PDB) entry 3F2U], Pc (PDB entry 1PDQ), and CHD1 (PDB entry 2B2W) are shown at the top, and those defined for the MSL3 chromo barrel domain (PDB entry 3M9P) are shown at the bottom. Subgroups within the chromodomain superfamily are colored separately. Residues highlighted in yellow form the aromatic cage. Those highlighted in magenta are additional aromatic residues known from structural studies to supplement the coordination of the methylated lysine. Those marked in bold are well-conserved residues structurally on the periphery of the aromatic cage, with nonconserved residues highlighted in black. Those highlighted in green are conserved phosphorylatable residues at the position of a residue known to be phosphorylated by casein kinase II in HP1. Those marked with an asterisk are notable residues conserved in chromodomains but not among chromo barrel domains.

ancestor, with its initial branch shared by the chromodomain Y-linked (CDY) proteins and the histone H3 lysine 9 (H3K9) methyltransferase suppressor of variegation 3–9 (Suv39) homologues. While structurally and functionally much more about the HP1/CBX proteins and their involvement in

methylated histone H3K9 or K27 recognition is understood, a methylated histone binding role is expected for other uncharacterized chromodomains within this subset given their ability in vitro to bind methylated histone lysines, and their colocalization with these histone marks.[5−8] The subfamily defined by the ATP-

dependent chromatin remodeling CHD proteins[9] is unique to the superfamily because its members possess two tandem chromodomains. Earlier work[10,11] has determined that these chromodomains could work cooperatively to recognize methylated histones. Within the CHD subfamily are three distinct groups, i.e., CHD1/2, CHD3/4/5, and CHD6/7/8/9. CHD1 is structurally better characterized than the others and together with CHD2 is also unique in its extended linker sequences found between the first two β-strands (β_1 and β_2) of the first chromodomain (Figure 1B). Furthermore, the first chromodomains of CHD1 and CHD2 seem to be closely related to the second chromodomains of the other CHD proteins, although the significance of this has yet to be established.

The third subfamily is characterized by several proteins that contain domains inconsistently classified as chromodomains by numerous automated domain predictor programs[12] but have been described structurally as chromo barrel domains.[13] These domains of mortality factor 4-like protein 1 (MORF4L1; MRG15 or Eaf3 in yeast) and male-specific lethal 3 (MSL3) strongly resemble the chromodomain and interact with methylated histone peptides, although their coordination is distinct from that of the classical chromodomain (discussed below). AT rich interactive domains 4A and 4B (ARID4A and ARID4B, respectively), of which little is known, might be expected to have similar methylated lysine binding properties on the basis of their sequence alignment, which may provide clues about their function. Key residues that are not conserved in these domains but are found in HP1 and related proteins provided the first indication that the fold was unlikely to be a canonical chromodomain[14] (see below and Figure 1B).

We note that the related chromoshadow domain, found C-terminal to the chromodomain of HP1 isoforms, would reside on a separate branch of the phylogenetic tree if included with the chromodomains, despite differing only slightly from the canonical topology with the addition of an α-helix N-terminal to β_1.[15,16] Only the second of the three aromatic cage residues is conserved, and the domain does not recognize methylated lysines. Instead, it forms a dimer to function as a protein−protein interaction domain.

CHROMODOMAIN-CONTAINING PROTEINS ARE GENERALLY INVOLVED IN CHROMATIN REMODELING

Chromodomain-containing proteins generally are modular, and many contain domain repeats in tandem (Figure 2). We observe that chromodomains belonging to the same subfamily (Figure 1) exhibit similar domain layouts, including the CHD protein subgroups.[11] It is interesting to note that all of the proteins contain chromodomains at their N-termini, with the exception of ARID4A and ARID4B, which have them in the middle of their sequences, and CHD3 and CHD4, whose tandem chromodomains are preceded by an N-terminal NUC034/HMG-box helicase (CHDN) domain and a tandem pair of plant homeodomain (PHD) fingers.

Some proteins contain related folds within their sequences. ARID4A and ARID4B contain an N-terminal Tudor domain, which is structurally related to the chromodomain and can recognize methylated lysines on both histone and non-histone proteins, and the HP1 proteins contain the chromoshadow domain at their C-termini. Other proteins contain domains that have been associated with chromatin remodeling, such as PHD fingers (found in CHD3 and CHD4), which can recognize methylated and unmethylated histone H3K4; Swi3p, Rsc8p,

and Moira (SWIRM) and Swi3, Ada2, N-CorR, TFIIIB (SANT) domains [found in SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily c members 1 and 2 (SMARCC1 and SMARCC2, respectively)], which recognize nucleosomal DNA; and the pre-Suv39, Enhancer-of-zeste, Trithorax (SET), SET, and post-SET domains (found in Suv39 homologues 1 and 2), which are associated with the catalytic activity of histone methyltransferases.

The functions of human chromodomain-containing proteins are predominantly related to chromatin remodeling and gene transcription, although several proteins are known for their involvement in DNA damage repair, differentiation, and senescence (Table 1). Most function as part of larger multiprotein complexes that effect transcriptional repression. Given these essential roles, up- or downregulation of gene expression is frequently observed in cancer and numerous other diseases. Beyond the human genome, interestingly, very few chromodomains have been found in proteins outside the nucleus, one notable exception being the chloroplast signal recognition particle protein cpSRP43 in *Arabidopsis*.[17] Its three chromodomains are most closely related to the second chromodomains of CHD6−9, although no methylated or unmethylated substrate has been identified.

CONTRIBUTIONS OF THE CHROMODOMAIN TO PROTEIN FUNCTION

The prototypical chromodomain, described within the HP1 proteins, recognizes di- and trimethylated histone H3K9,[18,19] which is essential for the recruitment of HP1 to sites of repressed chromatin (e.g., heterochromatin, for which HP1 is named). Similarly, the CBX proteins, with chromodomains similar in sequence and structure at their N-termini, are known to be recruited to di- or trimethylated H3K27 and function in a Polycomb repressive multiprotein complex involved in the regulation of genes associated with development and differentiation.[20] CDY1 was also shown to bind to H3K9me,[7] which points to a role in gene repression. Human CHD1 has been shown to recognize H3K4me, although, surprisingly, a single mark is bound by the tandem chromodomains[10] (see below). Unlike H3K9me and H3K27me, this mark is traditionally associated with active transcription. There is conflicting evidence regarding the ability of Chd1 to recognize H3K4me in yeast.[10,11,21−24] However, it appears that its localization and function are somewhat independent of H3K4 methylation.[25−30] Nevertheless, the chromodomains appear to be important for association with actively transcribed chromatin, and this is independent of methylation at H3K4 or K36, although these modifications may yet be important for Chd1/Rpd3S-mediated maintenance of chromatin structure during transcription.[28] It is interesting to note that Rpd3S subunit Eaf3 contains a chromo barrel domain capable of binding H3K36me3 (see below). Additionally, the chromodomains of Chd1, independent of direct histone modification interactions, counteract the activity of the facilitates chromatin transcription (FACT) complex.[25]

Thus far, the chromodomain has been predominantly characterized as a methylated histone lysine binding module. The chromodomain of HP1 has also been shown in vitro to bind to non-histone protein G9a, a histone methyltransferase, bearing a similar, conserved sequence flanking a self-methylated lysine,[31] although the function of this interaction is unclear. Nevertheless, this study shows that binding partners for the chromodomain are not necessarily restricted to histones, which has been shown for

Figure 2. Domain layout of human chromodomain-containing proteins. Chromo barrel domains are denoted with asterisks. Abbreviations: CD, chromodomain; RBB1NT, N-terminal to ARID/BRIGHT domain in Rb-binding protein 1 family; CHSH, chromoshadow domain; ANK, four ankyrin repeats; DEXDc, DEAD-like helicase domain; HELICc, helicase domain; HD-like, homeodomain-like; CHDN, N-terminal NUC034/HMG-box helicase domain; DUF1087 and DUF1086, domains without a known function; CHDCT2, C-terminal NUC038 helicase domain.

other structural folds. All Royal domains (except the plant Agenet domain) have been characterized as general methylated substrate binding modules, suggesting that their common ancestor also recognized methylated ligands.[3] While it is tempting to speculate that ligands for as yet uncharacterized chromodomains will be methylated lysines, we note that the Mi-2/nucleosome remodeling and deacetylase (NuRD) chromatin remodeling complex, of which CHD3 and CHD4 are a part, preferentially binds the unmodified H3 tail,[32,33] while neither pair of chromodomains in these proteins appears to have the residues expected to be important for methylated lysine binding.[24]

Chromodomains for which a binding substrate has not yet been identified also highlight the possibility of novel functions for the proteins that contain them. For example, the retrotransposon Tf1 integrase from *Schizosaccharomyces pombe*, which integrates into Pol II promoter regions, contains a chromodomain that has been directly implicated in the frequency of integration by mediating binding of Tf1 to DNA, as well as the selectivity of integration site targeting.[34] However, because the chromodomain is unable to directly associate with either DNA or histones, it is possible that Tf1 is regulated by the recognition of an as yet unidentified substrate and/or modification on chromatin.

Table 1. Functions of Chromodomain-Containing Proteins

protein[a]	functions in mammals[b]	functional contributions of chromodomains	human disease relevance
CBX1 | (HP1β)[19,56,69,77−82]	All HP1 isoforms: heterochromatin formation and transcriptional repression; interacts with SUV39H1; interacts with KAP1 and DNMT1 for euchromatic gene silencing; recruited to UV-induced DNA damage and double-strand breaks; dynamic exchange with other HP1 isoforms for maintaining stable hetero chromatic state; cell cycle-dependent localization	All HP1 isoforms: H3K9me binding, ejected by H3S10ph during M phase; possible localization by binding to H1.4K26me, ejected by H1.4S27ph; binds H3K23me1; multimerization mediated by CD for heterochromatin spreading (yeast). CBX1-specific: T51 phosphorylation with mobilization releases HP1β from chromatin	Low-level expression associated with melanoma progression
CBX3 (HP1γ)[19,56,78,80−83]	See CBX1. CBX3-specific: regulation of cell differentiation	See CBX1	
CBX5 (HP1α)[19,56,78,80−82,84,85]	See CBX1. CBX5-specific: interacts with linker H1; neuronal terminal differentiation; interacts with BRG1 to negatively regulate SWI/SNF chromatin remodeling	See CBX1	Alters invasive potential of breast cancer cells requiring HP1 dimerization but not PXVXL interaction
CBX2 (Pc1/M33)[5,35,70,86−88]	All Pc isoforms: chromatin recruitment module of Polycomb repressive complex 1 (PRC1), interacts with Ring1B; different isoforms have distinct localization and mobility patterns within chromatin; enriched on Xi (except CBX4). CBX2-specific: repression of ovarian development in XY gonads possibly by regulation of SRY or WT1	All Pc isoforms: H3K27me reader of PRC1. Differential affinities for H3K9me, H3K27me, and RNA (except CBX2 cannot bind RNA). CBX2-specific: S42 phosphorylation leads to minor changes in affinity for H3K9me and H3K27me	Overexpression in diploid breast carcinoma
CBX4 (Pc2)[5,35,86,89,90]	See CBX2. CBX4-specific: target of SENP2 desumoylation enzyme in cardiac development; SUMO E3 ligase; tumor suppressor	See CBX2	
CBX6[5,35,86,91]	See CBX2. CBX6-specific: distinct distribution and mobility properties, weaker interaction with endogenous Ring1B and Polycomb group target genes suggest a role different from that of other Pc isoforms, although chromobox can still bind Ring1B	Binds H3K27me3 weakly	
CBX7[5,92]	See CBX2. CBX7-specific: cellular lifespan extension and senescence; regulation of Ink4a/ARF locus; binds Xist RNA in X inactivation	See CBX2. CBX7-specific: association with RNA	Up- or downregulation in several cancers. Marker of poor prognosis. Initiates repression of genes silenced with cancer-specific DNA hypermethylation
CBX8 (Pc3)[5,35,93]	See CBX2. CBX8-specific: regulation of Ink4a/ARF locus, dependent on Bmi1	See CBX2. CBX8-specific: necessary for nuclear localization	
CDY1/2[6,7,94]	HAT with preference for H4, H4 hyperacetylation during spermatogenesis; colocalizes with CBX1/HP1b	Binds H3K9me1/2/3, H1.4K26me3, H3K27me2/3, G9aK185me1/3	Marker for various male sex chromosomal abnormalities

Table 1. Continued

protein[a]	functions in mammals[b]	functional contributions of chromodomains	human disease relevance
CDYL1 (CDYL)[94−96]	Spermatogenesis; transcriptional corepressor, binds HDACs and CoA; HAT activity in vitro; REST corepressor that interacts with REST and G9a	Methylation by G9a outside CD abolishes H3K9me3 interaction	
CDYL2[7,95]	Spermatogenesis	Binds H3K9me1/2/3, H1.4K26me3, H3K27me2/3, G9aK185me1/3	Upregulated in carcinomas, function in tumor progression, repress tumor suppressor gene expression
MPP8[97]	Probable involvement in M-phase functions, phosphorylation-dependent; localized to nucleus during interphase, throughout the cell during M phase	Binds H3K4me3; H3K9me2/3 binding leads to recruitment of E-cadherin and then DNMT3A	
SUV39H1 (KMT1A)[98−100]	HMT for H3K9me3 to establish constitutive pericentric heterochromatin; S-phase gene silencing during differentiation	Binding to H3K9me essential for spreading of heterochromatin (yeast Clr4)	ERα transcription in breast cancer; RB1 mutants found in human cancers cannot bind SUV39H1; higher-level expression in colorectal tumors; lymphomagenesis
SUV39H2 (KMT1B)[99,101]	Formation of pericentric heterochromatin via H3K9 trimethylation		SNP in 3′-UTR associated with increase in lung cancer risk
CHD1[10,102−104]	Regulation of RNA polymerase II transcription; ATP-dependent chromatin assembly; pluripotency of ESCs	Tandem CDs recognize H3K4me3. Acidic linker helix gates DNA access to ATPase motor	
CHD2[11,105,106]	Development, hematopoiesis, tumor suppression; kidney function	Binds H3K4me3 more weakly than CHD1, possibly gated by phosphorylation	Differential expression in urinary bladder cancer; translocation disruption results in scoliosis
CHD3 (Mi-2a)[10,44,107−109]	NuRD HDAC and repressive complex; transcriptional repression or coactivator of c-Myb	DNA binding by *Drosophila* Mi-2 CDs in nucleosome binding and mobilization	Dermatomyositis autoimmune disease resulting in autoantibodies against CHD3/4
CHD4 (Mi-2b)[44,107−110]	NuRD complex; checkpoint signaling and DNA damage repair; promotes CD4 gene expression during T cell development	See CHD3	See CHD3
CHD5[44,111]	Tumor suppressor that controls proliferation, apoptosis and senescence via the p19[ARF]/p53 pathway	See CHD3	Downregulated through promoter hypermethylation, mutation in several types of cancer
CHD6[11,112,113]	Interacts with Nrf2 transcription factor in cellular redox homeostasis; cell proliferation and radiosensitivity; transcription preinitiation and elongation via RNA pol II	Possible shared coordination of methylated lysine by both CDs	TCF4 translocation leads to mild retardation related to Pitt-Hopkins syndrome
CHD7[11,114−117]	Neural crest formation and cell motility; inner ear development; rRNA biogenesis; enhancer-mediated transcription	See CHD6	Mutations in CHARGE and Kallmann syndromes; idiopathic scoliosis
CHD8[118−121]	AR-mediated or β-catenin-mediated transcription; HOXA2 and cyclin E2 expression; interacts with CHD7; suppresses p53-mediated apoptosis	H3K4me2 binding to both CDs similar to CHD1, possible chromatin recruitment	Idiopathic developmental delay and cognitive impairment

Table 1. Continued

protein[a]	functions in mammals[b]	functional contributions of chromodomains	human disease relevance
CHD9[11,122]	Osteogenic cell differentiation	See CHD6	
TIP60 (KAT5)[123,124]	NuA4 HAT complex; tumor suppressor, apoptosis, DNA repair, cell cycle progression; H2A and H4 HAT, acetylation and activation of ATM	H3K9me3 binding activates HAT, dependent on DNA damage-induced displacement of HP1β from H3K9me3	Low levels in several cancers; prostate cancer cell proliferation; implicated in Alzheimer's disease
MYST1 (MOF/ MOZ)[125−127]	MSL H4K16 HAT complex; cell cycle, DNA repair; associates with H3K4 HMT MLL1 for transcriptional activation	Interaction with ATM	
ARID4A (RBBP1)[128−130]	mSIN3 HDAC complex; binds Rb, promotes repression and growth arrest		Leukemia suppressor gene
ARID4B (RBBP1L1)[129,130]	mSIN3 HDAC complex		Molecular marker for several cancers; leukemia suppressor gene
MORF4L1 (Eaf3/ MRG15)[131,132]	NuA4 HAT and mSIN3 complexes; transcriptional repression, cell proliferation and aging, DNA damage repair, gene splicing	Assembly of MAF2 complex (with MOF) and HAT activity	
MSL3 (MSL3L1)[127,133−135]	MSL H4K16 HAT complex; X inactivation	Nucleic acid (RNA, ssDNA) binding, H3K36me3 binding, X chromosome gene association, MSL complex spreading to active genes in cis	
SMARCC1 (BAF155)[136,137]	SWI/SNF, WINAC, BRG complexes; transcriptional activation and repression, heterochromatin formation, chromatin compaction during differentiation		Upregulated in prostate cancer, tumor recurrence
SMARCC2 (BAF170)[137−139]	SWI/SNF, WINAC, BRG complexes; transcriptional activation and repression		Reduced cell viability in primary chronic lymphocytic leukemia cells. Dysregulation in testicular germ cell, squamous non-small cell lung cancers

[a] References cited are representative only. We apologize to all authors whose work is not cited because of space limitations. [b] Abbreviations: CD, chromodomain; HAT, histone acetyltransferase; HMT, histone methyltransferase; HDAC, histone deacetylase.

Figure 3. Structures of chromodomains and chromo barrel domains. Secondary structure elements are labeled as defined in Figure 1B and the text. Residues interacting with the methylated lysine are labeled in the insets. (A) Chromodomain of uncomplexed HP1β (PDB entry 3F2U, magenta) and *Drosophila* Pc (PDB entry 1PDQ, red) in complex with the H3K27me3 peptide (yellow). (B) CHD1 (PDB entry 2B2W) chromodomains 1 (light purple) and 2 (dark blue) in complex with the H3K4me3 peptide (yellow). (C) Chromo barrel domain of Eaf3 (PDB entry 2K3Y, green) in a complex with the fused H3K36me2 peptide (purple) (left). MSL3 chromo barrel domain (PDB entry 3M9P, light green) in a complex with the H4K20me1 peptide (cyan) and DNA (orange) (right). The β-strand that mimics the H3 peptide of the Pc complex is denoted with an asterisk. The center image shows aromatic cage residues that coordinate the methylated lysine of the Pc—H3K27me3 (red and yellow), Eaf3—H3K36me2 (green and purple), and MSL3—H4K20me1 (light green and cyan) complexes.

The fact that the principal function defined for the chromodomain is the recognition of methylated lysine points to the possibility of cross-talk or competition between chromodomain-containing proteins and a requirement for additional interactions to confer specificity. For example, several CBX isoforms are able to bind methylated H3K27, yet they control the transcription of nonredundant genes and have unique chromatin localization patterns that depend upon multiple factors such as differentiation state and cell cycle stage.[35,36] It is believed that their unique C-terminal domains help establish this specificity. In *S. pombe*, Suv39 homologue Chp1 (which contains an H3K9me-recognizing chromodomain) assists in the methylation of H3K9 on newly deposited nucleosomes and recruits the RNA-induced transcriptional silencing (RITS) complex to chromatin. Acetylation at H3K4 ejects Chp1 from transcriptionally active heterochromatin, thus allowing the recruitment of Chp2/Swi6 (homologues of HP1), which is insensitive to the acetylation mark, to allow reassembly of heterochromatin at S/G$_2$.[37]

■ STRUCTURAL INSIGHTS INTO THE INTERACTION OF THE CHROMODOMAIN WITH METHYLATED LYSINE

The prototypical chromodomain of HP1 was the first to be characterized structurally at an atomic level and provided insight into its function as a methylated histone lysine binding domain[14,38,39] (Figure 3A). The fold is a curved antiparallel β-sheet comprising three strands (β_1–β_3) with helix α_1 occurring between β_2 and β_3 and helices α_2 and α_3 following β_3 (Figure 1B). The methylated histone peptide in the complex structure is accommodated by a hydrophobic groove and forms a β-strand that either contributes to the curved β-sheet,[40] mimicking the four-strand barrel found in Tudor domains, or forms a second smaller β-sheet with β_3 and the N-terminus of β_1[39] (Figure 3A). Histone recognition is accomplished by a conserved cage of three aromatic residue side chains [Y21, W42, and F45 in HP1β (Figure 1B)] that interacts with the methylated lysine moiety via cation−π interactions.[41] In

vitro measured affinities of a chromodomain for di- or trimethylated lysine ligands are typically in the micromolar range for most proteins and their presumed in vivo substrates.[5,10] The HP1−CBX chromodomain interaction is virtually the same for di- or trimethylated lysines, although the additional methyl group improves the affinity by allowing more polar and van der Waals interactions with the chromodomain binding pocket.[39,41] The second and third aromatic residues are within a highly conserved loop sequence of hydrophobic and basic residues between β_2 and β_3, and these two are far more conserved among all chromodomains than the first aromatic residue (Figure 1B). Interestingly, the first aromatic residue, which resides at the beginning of β_1, appears to be within a highly flexible region in the absence of a ligand, suggesting that the cage may not be preformed in the absence of the ligand (K. Yap and M.-M. Zhou, unpublished observations).

The interaction between chromodomain and methylated histone lysines extends beyond the methylated moiety. In all complex structures, but especially for the CBX chromodomains, several contacts are observed between the binding pocket of the chromodomain and residues up to three positions N-terminal of the methylated residue on the histone peptide. The interaction is more extensive for the CBX chromodomains, with a larger surface area buried by peptide binding.[40] Additional hydrogen bonds stabilize the β-strand formed by the histone peptide to extend the β-sheet.[42] In contrast, methylated ligands do not penetrate deeply into the pockets of the related MBT domains, which bind lower-state methylated lysines via a "cavity insertion recognition" mode.[43]

The CHD proteins contain two tandem chromodomains at their N-termini and have been implicated in chromatin remodeling. CHD1 is structurally the best characterized of the nine isoforms found in humans, and its two chromodomains bind to a single histone H3 peptide methylated at K4[10] (Figure 3B). The methylated lysine is coordinated in part by the latter two of the three aromatic residues (W322 and W325) that are conserved in most chromodomains (Figure 1B), although E272, which aligns with the first cage residue, faces toward the methyllysine moiety. Y295 within helix α_0, inserted between β_1 and β_2 of the first chromodomain, contributes to the binding of H3T3, K4me, and Q5. The equivalent cage residues of the second chromodomain (Q389, W413, and L416) do not participate in peptide coordination; instead, acidic residues within the insert (D408) and β_3 (E424) are in contact with H3A1. CHD2, which is closely related to CHD1 yet contains a longer insert within its second chromodomain (Figure 1), binds H3K4me with a much lower affinity and has been hypothesized to require an additional factor or modification to allow its full interaction with H3K4me.[11] CHD7 and CHD9 tandem chromodomains, which are in a subclass distinct from CHD1 and CHD2 and are related to CHD6 and CHD8 (Figure 1A), have also been demonstrated to interact in vitro with methylated histone peptides, while the chromodomains of CHD3 and CHD4, which are in a subclass with CHD5, appear to have greater affinity for DNA and do not require binding to histone tails to associate with chromatin.[44]

■ CHROMO BARREL DOMAINS

The chromo barrel domain is often misidentified as a chromodomain in the literature, despite their clear distinction within the phylogenetic tree (Figure 1A). SMART identifies some occurrences of these domains as Tudor knot folds. The chromo barrel domain contains a strand (β_0 in Figure 3C) that precedes the chromodomain fold, mimicking the strand formed by the methylated histone peptide in the chromodomain complex, and another strand, β_4, in the place of α_2 of the chromodomain; the N-terminal tail displaces the C-terminal helix such that it is packed against the β-barrel (Figure 3C). The latter two of three aromatic cage residues are conserved, and the first aromatic residue is found only in ARID4A/B and MORF4L1/MSL3 chromo barrel domains. Previously, the chromo barrel domain was characterized as an RNA-binding module, and mutation of the second aromatic cage residue of histone H4K16 acetyltransferase males absent on first (MOF/MYST1) was shown to abolish binding to rox2 noncoding RNA;[45] however, the interaction of the chromo barrel domain is believed to be necessary but not sufficient for interaction of MOF with RNA, while other regions outside the chromo barrel domain may be important.[46] Furthermore, no binding to modified histones was observed, leading to the suggestion that the lack of conservation of the first and third aromatic residues may distinguish this and other chromo barrel domains in terms of functionality.[13] Indeed, it was shown that other chromo barrel domains with these conserved residues could interact with methylated histone peptides in a manner somewhat similar to that of the chromodomains[47−49] but with ∼10−100-fold weaker affinities. To obtain a complex structure and circumvent the problem of poor affinity, Xu et al.[48] fused an H3K36me2 peptide to the C-terminus of the chromo barrel domain of yeast Eaf3 (Figure 3C, left). The structure illustrates how the methylated lysine still occupies the binding cleft coordinated by an aromatic cage, the rest of the peptide is oriented on the periphery of the surface, and the methylated lysine side chain is rotated 100° away from its position in the chromodomain complex structure (Figure 3C, center). A fourth aromatic residue that lies just outside the third cage residue and is otherwise only conserved in the CBX chromodomains provides additional contacts with the methylated lysine. Another study showed that the Rpd3S complex requires both the PHD finger from the Rco1 subunit and the chromodomain of Eaf3 to recognize H3K36-methylated nucleosomes,[50] suggesting how the interaction would occur in vivo. Recently, it was reported that the chromo barrel domain of MSL3 (a mammalian homologue of Eaf3) interacts with monomethylated H4K20, but only in the presence of DNA,[51] although a longer construct or induced dimerization of the domain may alleviate this requirement.[52] Unlike H3K36me2, this modification has been associated with active transcription,[53,54] genomic stability, and entry into prometaphase.[55] Moreover, the MSL3 chromo barrel domain in the presence of DNA does not interact with either H3K36me3 or H4K20me3.[52] The ternary structure of the MSL3 chromo barrel domain, the H4K20me1 peptide, and DNA (Figure 3C, right) shows that the monomethyl group inserts into a four-residue cage and is additionally hydrogen-bonded by a water molecule. Despite the requirement for DNA, which packs against the histone peptide, β_3, and the loop between β_3 and β_4 and the third and fourth cage residues, the position of the methylated peptide is very similar to that of the Eaf3-fused H3K36me2 complex structure. Eaf3 contains an extensive linker that contributes an additional strand and helix folding against the β-barrel[47,48] and would prevent a DNA interaction as observed in the MSL3 ternary complex. Another mammalian homologue of Eaf3, mortality factor related gene 15 (MRG15), which does not contain this linker, has also been shown to bind di- or trimethylated H3K36,[49] but its DNA binding capability has not been assessed; therefore, it is unclear if this is a general mode of recognition for these chromo barrel domains.

■ ALTERING THE SPECIFICITY AND FUNCTIONALITY OF THE CHROMODOMAIN

Binary Switch. Histone lysine residues that are methylated often occur adjacent to a serine or threonine residue, phosphorylation of which can block binding of the effector protein. This "binary methylation—phosphorylation switch" mechanism allows for the cell cycle-dependent regulation of chromatin binding proteins while maintaining the methylation throughout multiple generations. The binding of HP1 isoforms to chromatin is regulated in this manner; phosphorylation of H3S10 by the kinase Aurora B prevents interaction of the chromodomain with H3K9me3 during mitosis. Removal of HP1 from chromosomes during mitosis is thought to be a necessary step to allow for proper chromosome condensation and segregation. This allows the H3K9me3 mark to remain in place and recruit back HP1 when S10 is dephosphorylated at the end of mitosis.[56] This binary mechanism is not restricted to interactions involving H3K9me3, as H3T3 phosphorylation has been found to regulate H3K4 methyl interactions,[10,57] while H3S28 phosphorylation has been thought to regulate H3K27 methyl interactions with Polycomb group proteins.[58]

The molecular mechanism of the "binary switch" is explained by structures of HP1 chromodomain—H3K9me complexes that reveal how a bulky and negatively charged phosphate on S10 would disrupt the interaction and lead to expulsion from chromatin (Figure 4). In addition, it was proposed that the two modifications together on the tail might also assume a different conformation[59] that might further prevent association with the chromodomain. Furthermore, phosphorylation of H3T3 reduces the affinity of the CHD1 tandem chromodomains for an H3K4me3 peptide ~30-fold, and the structure shows that H3T3ph inserts into a cleft formed between the two chromodomains.[10] Phosphorylation of T3 during mitosis disrupts the binding of CHD1 to H3K4me3 in vivo, with dephosphorylation allowing CHD1 to bind again during telophase, suggesting the presence of another binary switch.

Dimerization via the Chromodomain. Recently, it was reported that HP1 homologue Swi6 in *S. pombe* binds to mononucleosomes as a tetramer, with dimerization occurring via both chromoshadow domains and chromodomains to establish specificity for the H3K9me mark on chromatin.[60] Mutations made to residues V82, immediately adjacent to the first aromatic cage residue Y81 in β_1, and Y131, within α_3, strengthen the chromodomain—chromodomain association and increase specificity significantly. Dimerization via the chromodomain may occur only in HP1, and while Y131 is well-conserved across all HP1/CBX and some CHD chromodomains, a hydrophobic residue at the V82 position is unique to HP1 isoforms. Notably, it has also been shown that both H3K9 methylation binding and oligomerization of CDYL1b are necessary for heterochromatin association, although how this would be mediated is unknown.[61]

Post-Translational Modifications to the Chromodomain. Little has been reported about post-translational modifications to the chromodomain affecting its activity, although phosphorylation, sumoylation, and acetylation have been reported to occur on many chromodomain-containing proteins. Phosphorylation and N6-acetylation sites found within chromodomains are for the most part the result of genomic-scale mass spectrometry studies, functionally uncharacterized, and often on nonconserved residues. Previously, several post-translational modifications within the HP1 isoforms were characterized, including lysine acetylation and methylation throughout both chromodomain and chromoshadow domains, and formylation at highly


Figure 4. Depiction of H3K9me3 and S10 side chains in the Pc—H3K27me3 structure, with Pc depicted in surface representation. Polar contacts made between the side chain of Pc E58 and H3S10 (backbone nitrogen colored blue and side chain oxygen colored red and denoted Oγ) illustrate how phosphorylation at S10 could disrupt the interaction. Aromatic cage residue side chains are also shown in stick representation.

conserved lysines adjacent to the second aromatic cage residue.[62] Casein kinase II (CKII) is a kinase found associated with several chromodomain-containing proteins, including HP1,[63] CBX8,[64,65] and CHD1.[66] Phosphorylation at S15 at the N-terminus of *Drosophila* HP1 by CKII leads to a large decrease in the level of binding of HP1 to heterochromatin;[63,67] however, this residue is not conserved in mammalian HP1 or CBX proteins. Conversely, phosphorylation at two serine residues (S11 and S14) by CKII at the N-terminus of mammalian HP1α was shown to increase the affinity for methylated H3K9, although the effect may be predominantly due to the direct interaction of HP1α with K14 and K18 on the H3 tail, C-terminal to methylated K9.[68] Phosphorylation by CKII of a well-conserved threonine, T51, on HP1β (Figure 1B) that lies just outside the aromatic cage is important for HP1β mobilization and leads to phosphorylation of histone H2AX and initiation of the DNA damage response.[69] Phosphorylation or mutation of this residue has been shown to abolish binding to H3K9me3, potentially because of the disruption of hydrogen bonds that normally stabilize interaction with the methylated lysine. In contrast, another study showed that CKII treatment of mouse CBX2 results in modestly increased affinity for H3K27me3 and slightly decreased affinity for H3K9me3.[70] However, because CKII may phosphorylate CBX2 at multiple sites, this change in binding affinity may not be due to phosphorylation at the site equivalent to HP1β T51.

Binding of Nucleic Acids to the Chromodomain. In addition to the characterization of some chromo barrel domains as RNA binding modules (see above), some of chromodomains have been characterized as nucleic acid binding domains, which had been suggested given the chromodomain's structural similarity to the oligonucleotide/oligosaccharide binding (OB) fold.[71] The tandem domains of *Drosophila* Mi-2 (a homologue of CHD3) are required for its ATPase activity and associate with nucleosomes in a manner independent of histone tail binding, instead preferentially binding DNA.[44] HP1 recruitment has been suggested to be dependent on RNA transcripts, although it has not been demonstrated that any binding is direct[72] and, if so, whether the interaction would occur through the chromodomain; a hinge region between the chromodomain and chromoshadow domain has been shown to bind RNA that, coordinated with methylated lysine binding by the chromodomain, allows HP1α to be recruited to heterochromatin.[73] Furthermore, this hinge region may be important for nonspecific DNA and linker histone binding in native chromatin in which the H3K9me mark is inaccessible.[74]

The chromodomains of several mammalian CBX isoforms were shown to interact with RNA, suggesting a mechanism for

how these proteins can associate with an inactive X chromosome in silencing, and mutations within the aromatic cage of CBX7 result in disruption of Xi localization, suggesting that binding the noncoding RNA is important for the recruitment of CBX7 to target loci.[5] Recently, we reported that interactions of both H3K27me and RNA with the CBX7 chromodomain, which employs slightly overlapping yet distinct surfaces for binding, are necessary for its function in controlling senescence and modulating $p16^{INK4a}$ repression.[75] Binding of the two ligands is negatively cooperative, suggesting that local concentrations of either the H3K27me mark or RNA at the target locus may dictate what is bound to CBX7. Although noncoding RNA has been increasingly recognized as an important factor in transcriptional control, to the best of our knowledge this is the only chromodomain that has been functionally characterized as both a methylated lysine binding module and an RNA binding domain, for which both interactions appear to be important for its targeting and retention at its target locus. Although it is structurally distinct from a chromodomain, the recent study of the ternary complex of the MSL3 chromo barrel domain, H4K20me1, and DNA suggests a novel multinucleosomal interaction with the MSL3 protein[51] that offers yet another tantalizing model for chromodomain-mediated gene recruitment and transcriptional regulation.

■ CONCLUSIONS

Most chromodomains found in the human genome function as methylated histone lysine binding domains via conserved residues, facilitating recruitment to chromatin. Other functions, such as nucleic acid recognition, may be mediated by residues unique to each chromodomain. More diverse functions are associated with chromodomain-containing proteins because of other modular domains that work in concert with the methylated lysine binding capacity. It remains to be seen if other histone modifications are capable of being recognized by the chromodomain, as is the case of the PHD finger,[76] but evolutionary evidence suggests this is less likely. Instead, we may expect to see more examples of nucleic acid and histone methylation corecognition, or post-translational modifications to the chromodomain, as more accurate portrayals of chromodomain function in vivo.

■ AUTHOR INFORMATION

Corresponding Author
*E-mail: ming-ming.zhou@mssm.edu. Phone: (212) 659-8762. Fax: (212) 849-2456.

■ ABBREVIATIONS

ARID4A, AT rich interactive domain 4A; CBX, chromobox; CDY, chromodomain-Y-linked; CHD, chromodomain helicase DNA-binding; CHDN, N-terminal NUC034/HMG-box helicase domain; CKII, casein kinase II; FACT, facilitates chromatin transcription; HP1, heterochromatin protein 1; MBT, malignant brain tumor; MOF, males absent on first; MORF4L1, mortality factor 4-like protein 1; MRG15, mortality factor-related gene 15; MSL3, male-specific lethal 3; NuRD, Mi-2/nucleosome remodeling and deacetylase; OB fold, oligonucleotide/oligosaccaride binding fold; Pc, Polycomb; PHD, plant homeodomain; RITS, RNA-induced transcriptional silencing; SANT, Swi3, Ada2, N-CorR, TFIIIB; SET, Su(var)3−9, enhancer-of-zeste, Trithorax; SMARCC1, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily c member 1; Su(var)3−9, suppressor of variegation 3−9; SWIRM, Swi3p, Rsc8p, and Moira.

■ REFERENCES

(1) Yap, K. L., and Zhou, M. M. (2010) Keeping it in the family: Diverse histone recognition by conserved structural folds. *Crit. Rev. Biochem. Mol. Biol. 45*, 488–505.

(2) Paro, R., and Hogness, D. (1991) The Polycomb protein shares a homologous domain with a heterochromatin-associated protein of *Drosophila*. *Proc. Natl. Acad. Sci. U.S.A. 88*, 263–267.

(3) Maurer-Stroh, S., Dickens, N., Hughes-Davies, L., Kouzarides, T., Eisenhaber, F., and Ponting, C. (2003) The Tudor domain 'Royal Family': Tudor, plant Agenet, Chromo, PWWP and MBT domains. *Trends Biochem. Sci. 28*, 69–74.

(4) Sanchez, R., and Zhou, M. M. (2009) The role of human bromodomains in chromatin biology and gene transcription. *Curr. Opin. Drug Discovery Dev. 12*, 659–665.

(5) Bernstein, E., Duncan, E. M., Masui, O., Gil, J., Heard, E., and Allis, C. D. (2006) Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. *Mol. Cell. Biol. 26*, 2560–2569.

(6) Kim, J., Daniel, J., Espejo, A., Lake, A., Krishna, M., Xia, L., Zhang, Y., and Bedford, M. T. (2006) Tudor, MBT and chromo domains gauge the degree of lysine methylation. *EMBO Rep. 7*, 397–403.

(7) Fischle, W., Franz, H., Jacobs, S. A., Allis, C. D., and Khorasanizadeh, S. (2008) Specificity of the chromodomain Y chromosome family of chromodomains for lysine-methylated ARK(S/T) motifs. *J. Biol. Chem. 283*, 19626–19635.

(8) Schalch, T., Job, G., Noffsinger, V. J., Shanker, S., Kuscu, C., Joshua-Tor, L., and Partridge, J. F. (2009) High-affinity binding of Chp1 chromodomain to K9 methylated histone H3 is required to establish centromeric heterochromatin. *Mol. Cell 34*, 36–46.

(9) Delmas, V., Stokes, D. G., and Perry, R. P. (1993) A mammalian DNA-binding protein that contains a chromodomain and an SNF2/SWI2-like helicase domain. *Proc. Natl. Acad. Sci. U.S.A. 90*, 2414–2418.

(10) Flanagan, J. F., Mi, L. Z., Chruszcz, M., Cymborowski, M., Clines, K. L., Kim, Y., Minor, W., Rastinejad, F., and Khorasanizadeh, S. (2005) Double chromodomains cooperate to recognize the methylated histone H3 tail. *Nature 438*, 1181–1185.

(11) Flanagan, J. F., Blus, B. J., Kim, D., Clines, K. L., Rastinejad, F., and Khorasanizadeh, S. (2007) Molecular implications of evolutionary differences in CHD double chromodomains. *J. Mol. Biol. 369*, 334–342.

(12) Brehm, A., Tufteland, K. R., Aasland, R., and Becker, P. B. (2004) The many colours of chromodomains. *BioEssays 26*, 133–140.

(13) Nielsen, P., Nietlispach, D., Buscaino, A., Warner, R., Akhtar, A., Murzin, A., Murzina, N., and Laue, E. (2005) Structure of the chromo barrel domain from the MOF acetyltransferase. *J. Biol. Chem. 280*, 32326–32331.

(14) Nielsen, P., Nietlispach, D., Mott, H., Callaghan, J., Bannister, A., Kouzarides, T., Murzin, A., Murzina, N., and Laue, E. (2002) Structure of the HP1 chromodomain bound to histone H3 methylated at lysine 9. *Nature 416*, 103–107.

(15) Brasher, S., Smith, B., Fogh, R., Nietlispach, D., Thiru, A, Nielsen, P., Broadhurst, R., Ball, L., Murzina, N., and Laue, E. (2000) The structure of mouse HP1 suggests a unique mode of single peptide recognition by the shadow chromo domain dimer. *EMBO J. 19*, 1587–1597.

(16) Cowieson, N. P., Partridge, J. F., Allshire, R. C., and McLaughlin, P. J. (2000) Dimerisation of a chromo shadow domain and distinctions from the chromodomain as revealed by structural analysis. *Curr. Biol. 10*, 517–525.

(17) Stengel, K. F., Holdermann, I., Cain, P., Robinson, C., Wild, K., and Sinning, I. (2008) Structural basis for specific substrate recognition by the chloroplast signal recognition particle protein cpSRP43. *Science* 321, 253–256.

(18) Bannister, A., Zegerman, P., Partridge, J., Miska, E., Thomas, J., Allshire, R., and Kouzarides, T. (2001) Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. *Nature* 410, 120–124.

(19) Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., and Jenuwein, T. (2001) Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. *Nature* 410, 116–120.

(20) Bracken, A. P., Dietrich, N., Pasini, D., Hansen, K. H., and Helin, K. (2006) Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. *Genes Dev.* 20, 1123–1136.

(21) McDaniel, I. E., Lee, J. M., Berger, M. S., Hanagami, C. K., and Armstrong, J. A. (2008) Investigations of CHD1 function in transcription and development of *Drosophila melanogaster*. *Genetics* 178, 583–587.

(22) Pray-Grant, M., Daniel, J., Schieltz, D., Yates, J., and Grant, P. (2005) Chd1 chromodomain links histone H3 methylation with SAGA- and SLIK-dependent acetylation. *Nature* 433, 434–438.

(23) Santos-Rosa, H., Schneider, R., Bernstein, B. E., Karabetsou, N., Morillon, A., Weise, C., Schreiber, S. L., Mellor, J., and Kouzarides, T. (2003) Methylation of histone H3 K4 mediates association of the Isw1p ATPase with chromatin. *Mol. Cell* 12, 1325–1332.

(24) Sims, R. J., III, Chen, C. F., Santos-Rosa, H., Kouzarides, T., Patel, S. S., and Reinberg, D. (2005) Human but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its tandem chromodomains. *J. Biol. Chem.* 280, 41789–41792.

(25) Biswas, D., Dutta-Biswas, R., and Stillman, D. J. (2007) Chd1 and yFACT act in opposition in regulating transcription. *Mol. Cell. Biol.* 27, 6279–6287.

(26) Biswas, D., Takahata, S., Xin, H., Dutta-Biswas, R., Yu, Y., Formosa, T., and Stillman, D. J. (2008) A role for Chd1 and Set2 in negatively regulating DNA replication in *Saccharomyces cerevisiae*. *Genetics* 178, 649–659.

(27) Eissenberg, J. C., Lee, M. G., Schneider, J., Ilvarsonn, A., Shiekhattar, R., and Shilatifard, A. (2007) The trithorax-group gene in *Drosophila* little imaginal discs encodes a trimethylated histone H3 Lys4 demethylase. *Nat. Struct. Mol. Biol.* 14, 344–346.

(28) Quan, T. K., and Hartzog, G. A. (2010) Histone H3K4 and K36 methylation, Chd1 and Rpd3S oppose the functions of *Saccharomyces cerevisiae* Spt4-Spt5 in transcription. *Genetics* 184, 321–334.

(29) Srinivasan, S., Armstrong, J. A., Deuring, R., Dahlsveen, I. K., McNeill, H., and Tamkun, J. W. (2005) The Drosophila trithorax group protein Kismet facilitates an early step in transcriptional elongation by RNA Polymerase II. *Development* 132, 1623–1635.

(30) Srinivasan, S., Dorighi, K. M., and Tamkun, J. W. (2008) *Drosophila* Kismet regulates histone H3 lysine 27 methylation and early elongation by RNA polymerase II. *PLoS Genet.* 4, e1000217.

(31) Sampath, S. C., Marazzi, I., Yap, K. L., Sampath, S. C., Krutchinsky, A. N., Mecklenbräuker, I., Viale, A., Rudensky, E., Zhou, M.-M., Chait, B. T., and Tarakhovsky, A. (2007) Methylation of a histone mimic within the histone methyltransferase G9a regulates protein complex assembly. *Mol. Cell* 27, 596–608.

(32) Nishioka, K., Chuikov, S., Sarma, K., Erdjument-Bromage, H., Allis, C., Tempst, P., and Reinberg, D. (2002) Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. *Genes Dev.* 16, 479–489.

(33) Zegerman, P., Canas, B., Pappin, D., and Kouzarides, T. (2002) Histone H3 lysine 4 methylation disrupts binding of nucleosome remodeling and deacetylase (NuRD) repressor complex. *J. Biol. Chem.* 277, 11621–11624.

(34) Chatterjee, A. G., Leem, Y. E., Kelly, F. D., and Levin, H. L. (2009) The chromodomain of Tf1 integrase promotes binding to cDNA and mediates target site selection. *J. Virol.* 83, 2675–2685.

(35) Ren, X., Vincenz, C., and Kerppola, T. K. (2008) Changes in the distributions and dynamics of polycomb repressive complexes during embryonic stem cell differentiation. *Mol. Cell. Biol.* 28, 2884–2895.

(36) Vincenz, C., and Kerppola, T. K. (2008) Different polycomb group CBX family proteins associate with distinct regions of chromatin using nonhomologous protein sequences. *Proc. Natl. Acad. Sci. U.S.A.* 105, 16572–16577.

(37) Xhemalce, B., and Kouzarides, T. (2010) A chromodomain switch mediated by histone H3 Lys 4 acetylation regulates heterochromatin assembly. *Genes Dev.* 24, 647–652.

(38) Ball, L. J., Murzina, N. V., Broadhurst, R. W., Raine, A. R., Archer, S. J., Stott, F. J., Murzin, A. G., Singh, P. B., Domaille, P. J., and Laue, E. D. (1997) Structure of the chromatin binding (chromo) domain from mouse modifier protein 1. *EMBO J.* 16, 2473–2481.

(39) Jacobs, S., and Khorasanizadeh, S. (2002) Structure of HP1 chromodomain bound to a lysine 9-methylated histone H3 tail. *Science* 295, 2080–2083.

(40) Fischle, W., Wang, Y., Jacobs, S., Kim, Y., Allis, C., and Khorasanizadeh, S. (2003) Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. *Genes Dev.* 17, 1870–1881.

(41) Hughes, R. M., Wiggins, K. R., Khorasanizadeh, S., and Waters, M. L. (2007) Recognition of trimethyllysine by a chromodomain is not driven by the hydrophobic effect. *Proc. Natl. Acad. Sci. U.S.A.* 104, 11184–11188.

(42) Min, J., Zhang, Y., and Xu, R. M. (2003) Structural basis for specific binding of Polycomb chromodomain to histone H3 methylated at Lys 27. *Genes Dev.* 17, 1823–1828.

(43) Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., and Patel, D. J. (2007) How chromatin-binding modules interpret histone modifications: Lessons from professional pocket pickers. *Nat. Struct. Mol. Biol.* 14, 1025–1040.

(44) Bouazoune, K., Mitterweger, A., Längst, G., Imhof, A., Akhtar, A., Becker, P. B., and Brehm, A. (2002) The dMi-2 chromodomains are DNA binding modules important for ATP-dependent nucleosome mobilization. *EMBO J.* 21, 2430–2440.

(45) Akhtar, A., Zink, D., and Becker, P. (2000) Chromodomains are protein-RNA interaction modules. *Nature* 407, 405–409.

(46) Buscaino, A., Kocher, T., Kind, J. H., Holz, H., Taipale, M., Wagner, K., Wilm, M., and Akhtar, A. (2003) MOF-regulated acetylation of MSL-3 in the *Drosophila* dosage compensation complex. *Mol. Cell* 11, 1265–1277.

(47) Sun, B., Hong, J., Zhang, P., Dong, X., Shen, X., Lin, D., and Ding, J. (2008) Molecular basis of the interaction of *Saccharomyces cerevisiae* Eaf3 chromo domain with methylated H3K36. *J. Biol. Chem.* 283, 36504–36512.

(48) Xu, C., Cui, G., Botuyan, M. V., and Mer, G. (2008) Structural basis for the recognition of methylated histone H3K36 by the Eaf3 subunit of histone deacetylase complex Rpd3S. *Structure* 16, 1740–1750.

(49) Zhang, P., Du, J., Sun, B., Dong, X., Xu, G., Zhou, J., Huang, Q., Liu, Q., Hao, Q., and Ding, J. (2006) Structure of human MRG15 chromo domain and its binding to Lys36-methylated histone H3. *Nucleic Acids Res.* 34, 6621–6628.

(50) Li, B., Gogol, M., Carey, M., Lee, D., Seidel, C., and Workman, J. (2007) Combined action of PHD and chromo domains directs the Rpd3S HDAC to transcribed chromatin. *Science* 316, 1050–1054.

(51) Kim, D., Blus, B. J., Chandra, V., Huang, P., Rastinejad, F., and Khorasanizadeh, S. (2010) Corecognition of DNA and a methylated histone tail by the MSL3 chromodomain. *Nat. Struct. Mol. Biol.* 17, 1027–1029.

(52) Moore, S. A., Ferhatoglu, Y., Jia, Y., Al-Jiab, R. A., and Scott, M. J. (2010) Structural and biochemical studies on the chromo-barrel domain of male specific lethal 3 (MSL3) reveal a binding preference for mono or dimethyl lysine 20 on histone H4. *J. Biol. Chem.* 285, 40879–40890.

(53) Barski, A., Cuddapah, S., Cui, K., Roh, T., Schones, D., Wang, Z., Wei, G., Chepelev, I., and Zhao, K. (2007) High-resolution profiling of histone methylations in the human genome. *Cell* 129, 823–837.

(54) Vakoc, C., Mandat, S., Olenchock, B., and Blobel, G. (2005) Histone H3 lysine 9 methylation and HP1γ are associated with transcription elongation through mammalian chromatin. *Mol. Cell* 19, 381–391.

(55) Houston, S. I., McManus, K. J., Adams, M. M., Sims, J. K., Carpenter, P. B., Hendzel, M. J., and Rice, J. C. (2008) Catalytic function of the PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for mitotic entry and genomic stability. *J. Biol. Chem. 283*, 19478–19488.

(56) Fischle, W., Tseng, B. S., Dormann, H. L., Ueberheide, B. M., Garcia, B. A., Shabanowitz, J., Hunt, D. F., Funabiki, H., and Allis, C. D. (2005) Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation. *Nature 438*, 1116–1122.

(57) Varier, R. A., Outchkourov, N. S., de Graaf, P., van Schaik, F. M., Ensing, H. J., Wang, F., Higgins, J. M., Kops, G. J., and Timmers, H. T. (2010) A phospho/methyl switch at histone H3 regulates TFIID association with mitotic chromosomes. *EMBO J. 29*, 3967–3978.

(58) Niessen, H. E., Demmers, J. A., and Voncken, J. W. (2009) Talking to chromatin: Post-translational modulation of polycomb group function. *Epigenet. Chromatin 2*, 10.

(59) Eberlin, A., Grauffel, C., Oulad-Abdelghani, M., Robert, F., Torres-Padilla, M. E., Lambrot, R., Spehner, D., Ponce-Perez, L., Wurtz, J. M., Stote, R. H., Kimmins, S., Schultz, P., Dejaegere, A., and Tora, L. (2008) Histone H3 tails containing dimethylated lysine and adjacent phosphorylated serine modifications adopt a specific conformation during mitosis and meiosis. *Mol. Cell. Biol. 28*, 1739–1754.

(60) Canzio, D., Chang, E. Y., Shankar, S., Kuchenbecker, K. M., Simon, M. D., Madhani, H. D., Narlikar, G. J., and Al-Sady, B. (2011) Chromodomain-mediated oligomerization of HP1 suggests a nucleosome-bridging mechanism for heterochromatin assembly. *Mol. Cell 41*, 67–81.

(61) Franz, H., Mosch, K., Soeroes, S., Urlaub, H., and Fischle, W. (2009) Multimerization and H3K9me3 binding are required for CDYL1b heterochromatin association. *J. Biol. Chem. 284*, 35049–35059.

(62) LeRoy, G., Weston, J. T., Zee, B. M., Young, N. L., Plazas-Mayorca, M. D., and Garcia, B. A. (2009) Heterochromatin protein 1 is extensively decorated with histone code-like post-translational modifications. *Mol. Cell. Proteomics 8*, 2432–2442.

(63) Zhao, T., and Eissenberg, J. C. (1999) Phosphorylation of heterochromatin protein 1 by casein kinase II is required for efficient heterochromatin binding in *Drosophila. J. Biol. Chem. 274*, 15095–15100.

(64) Dietrich, N., Bracken, A. P., Trinh, E., Schjerling, C. K., Koseki, H., Rappsilber, J., Helin, K., and Hansen, K. H. (2007) Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. *EMBO J. 26*, 1637–1648.

(65) Sánchez, C., Sánchez, I., Demmers, J. A. A., Rodriguez, P., Stroboulis, J., and Vidal, M. (2007) Proteomics analysis of Ring1B/Rnf2 interactors identifies a novel complex with the Fbxl10/Jhdm1B histone demethylase and the Bcl6 interacting corepressor. *Mol. Cell. Proteomics 6*, 820–834.

(66) Krogan, N. J., Kim, M., Ahn, S. H., Zhong, G., Kobor, M. S., Cagney, G., Emili, A., Shilatifard, A., Buratowski, S., and Greenblatt, J. F. (2002) RNA polymerase II elongation factors of *Saccharomyces cerevisiae*: A targeted proteomics approach. *Mol. Cell. Biol. 22*, 6979–6992.

(67) Zhao, T., Heyduk, T., and Eissenberg, J. C. (2001) Phosphorylation site mutations in heterochromatin protein 1 (HP1) reduce or eliminate silencing activity. *J. Biol. Chem. 276*, 9512–9518.

(68) Hiragami-Hamada, K., Shinmyozu, K., Hamada, D., Tatsu, Y., Uegaki, K., Fujiwara, S., and Nakayama, J. I. (2011) N-Terminal phosphorylation of HP1α promotes its chromatin binding. *Mol. Cell. Biol.* in press.

(69) Ayoub, N., Jeyasekharan, A. D., Bernal, J. A., and Venkitaraman, A. R. (2008) HP1-β mobilization promotes chromatin changes that initiate the DNA damage response. *Nature 453*, 682–686.

(70) Hatano, A., Matsumoto, M., Higashinakagawa, T., and Nakayama, K. I. (2010) Phosphorylation of the chromodomain changes the binding specificity of Cbx2 for methylated histone H3. *Biochem. Biophys. Res. Commun. 397*, 93–99.

(71) Eissenberg, J. C. (2001) Molecular biology of the chromodomain: An ancient chromatin module comes of age. *Gene 275*, 19–29.

(72) Piacentini, L., Fanti, L., Berloco, M., Perrini, B., and Pimpinelli, S. (2003) Heterochromatin protein 1 (HP1) is associated with induced gene expression in *Drosophila* euchromatin. *J. Cell Biol. 161*, 707–714.

(73) Muchardt, C., Guilleme, M., Seeler, J.-S., Trouche, D., Dejean, A., and Yaniv, M. (2002) Coordinated methyl and RNA binding is required for heterochromatin localization of mammalian HP1α. *EMBO Rep. 3*, 975–981.

(74) Meehan, R., Kao, C., and Pennings, S. (2003) HP1 binding to native chromatin in vitro is determined by the hinge region and not by the chromodomain. *EMBO J. 22*, 3164–3174.

(75) Yap, K. L., Li, S., Munoz-Cabello, A. M., Raguz, S., Zeng, L., Mujtaba, S., Gil, J., Walsh, M. J., and Zhou, M. M. (2010) Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. *Mol. Cell 38*, 662–674.

(76) Zeng, L., Zhang, Q., Li, S., Plotnikov, A. N., Walsh, M. J., and Zhou, M. M. (2010) Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPF3b. *Nature 466*, 258–262.

(77) Nishimura, K., Hirokawa, Y. S., Mizutani, H., and Shiraishi, T. (2006) Reduced heterochromatin protein 1-β (HP1β) expression is correlated with increased invasive activity in human melanoma cells. *Anticancer Res. 26*, 4349–4356.

(78) Smallwood, A., Esteve, P. O., Pradhan, S., and Carey, M. (2007) Functional cooperation between HP1 and DNMT1 mediates gene silencing. *Genes Dev. 21*, 1169–1178.

(79) Luijsterburg, M. S., Dinant, C., Lans, H., Stap, J., Wiernasz, E., Lagerwerf, S., Warmerdam, D. O., Lindh, M., Brink, M. C., Dobrucki, J. W., Aten, J. A., Fousteri, M. I., Jansen, G., Dantuma, N. P., Vermeulen, W., Mullenders, L. H., Houtsmuller, A. B., Verschure, P. J., and van Driel, R. (2009) Heterochromatin protein 1 is recruited to various types of DNA damage. *J. Cell Biol. 185*, 577–586.

(80) Aagaard, L., Laible, G., Selenko, P., Schmid, M., Dorn, R., Schotta, G., Kuhfittig, S., Wolf, A., Lebersorger, A., Singh, P. B., Reuter, G., and Jenuwein, T. (1999) Functional mammalian homologues of the *Drosophila* PEV-modifier Su(var)3−9 encode centromere-associated proteins which complex with the heterochromatin component M31. *EMBO J. 18*, 1923–1938.

(81) Cheutin, T., McNairn, A. J., Jenuwein, T., Gilbert, D. M., Singh, P. B., and Misteli, T. (2003) Maintenance of stable heterochromatin domains by dynamic HP1 binding. *Science 299*, 721–725.

(82) Ayyanathan, K., Lechner, M. S., Bell, P., Maul, G. G., Schultz, D. C., Yamada, Y., Tanaka, K., Torigoe, K., and Rauscher, F. J., III (2003) Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. *Genes Dev. 17*, 1855–1869.

(83) Takanashi, M., Oikawa, K., Fujita, K., Kudo, M., Kinoshita, M., and Kuroda, M. (2009) Heterochromatin protein 1γ epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers. *Am. J. Pathol. 174*, 309–316.

(84) Norwood, L. E., Moss, T. J., Margaryan, N. V., Cook, S. L., Wright, L., Seftor, E. A., Hendrix, M. J., Kirschmann, D. A., and Wallrath, L. L. (2006) A requirement for dimerization of HP1Hsα in suppression of breast cancer invasion. *J. Biol. Chem. 281*, 18668–18676.

(85) Lavigne, M., Eskeland, R., Azebi, S., Saint-Andre, V., Jang, S. M., Batsche, E., Fan, H. Y., Kingston, R. E., Imhof, A., and Muchardt, C. (2009) Interaction of HP1 and Brg1/Brm with the globular domain of histone H3 is required for HP1-mediated repression. *PLoS Genet. 5*, e1000769.

(86) Satijn, D. P., and Otte, A. P. (1999) RING1 interacts with multiple Polycomb-group proteins and displays tumorigenic activity. *Mol. Cell. Biol. 19*, 57–68.

(87) Biason-Lauber, A., Konrad, D., Meyer, M., DeBeaufort, C., and Schoenle, E. J. (2009) Ovaries and female phenotype in a girl with 46,XY karyotype and mutations in the CBX2 gene. *Am. J. Hum. Genet. 84*, 658–663.

(88) Parris, T. Z., Danielsson, A., Nemes, S., Kovacs, A., Delle, U., Fallenius, G., Mollerstrom, E., Karlsson, P., and Helou, K. (2010) Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. *Clin. Cancer Res. 16*, 3860–3874.

(89) Kagey, M. H., Melhuish, T. A., and Wotton, D. (2003) The polycomb protein Pc2 is a SUMO E3. *Cell 113*, 127–137.

(90) Kang, X., Qi, Y., Zuo, Y., Wang, Q., Zou, Y., Schwartz, R. J., Cheng, J., and Yeh, E. T. (2010) SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. *Mol. Cell 38*, 191–201.

(91) Bezsonova, I., Walker, J. R., Bacik, J. P., Duan, S., Dhe-Paganon, S., and Arrowsmith, C. H. (2009) Ring1B contains a ubiquitin-like docking module for interaction with Cbx proteins. *Biochemistry 48*, 10542–10548.

(92) Gil, J., Bernard, D., Martinez, D., and Beach, D. (2004) Polycomb CBX7 has a unifying role in cellular lifespan. *Nat. Cell Biol. 6*, 67–72.

(93) Bracken, A. P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, C., Theilgaard-Mönch, K., Minucci, S., Porse, B. T., Marine, J.-C., Hansen, K. H., and Helin, K. (2007) The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. *Genes Dev. 21*, 525–530.

(94) Lahn, B. T., Tang, Z. L., Zhou, J., Barndt, R. J., Parvinen, M., Allis, C. D., and Page, D. C. (2002) Previously uncharacterized histone acetyltransferases implicated in mammalian spermatogenesis. *Proc. Natl. Acad. Sci. U.S.A. 99*, 8707–8712.

(95) Caron, C., Pivot-Pajot, C., van Grunsven, L. A., Col, E., Lestrat, C., Rousseaux, S., and Khochbin, S. (2003) Cdyl: A new transcriptional co-repressor. *EMBO Rep. 4*, 877–882.

(96) Rathert, P., Dhayalan, A., Murakami, M., Zhang, X., Tamas, R., Jurkowska, R., Komatsu, Y., Shinkai, Y., Cheng, X., and Jeltsch, A. (2008) Protein lysine methyltransferase G9a acts on non-histone targets. *Nat. Chem. Biol. 4*, 344–346.

(97) Kokura, K., Sun, L., Bedford, M. T., and Fang, J. (2010) Methyl-H3K9-binding protein MPP8 mediates E-cadherin gene silencing and promotes tumour cell motility and invasion. *EMBO J. 29*, 3673–3687.

(98) Nielsen, S. J., Schneider, R., Bauer, U. M., Bannister, A. J., Morrison, A., O'Carroll, D., Firestein, R., Cleary, M., Jenuwein, T., Herrera, R. E., and Kouzarides, T. (2001) Rb targets histone H3 methylation and HP1 to promoters. *Nature 412*, 561–565.

(99) Rice, J. C., Briggs, S. D., Ueberheide, B., Barber, C. M., Shabanowitz, J., Hunt, D. F., Shinkai, Y., and Allis, C. D. (2003) Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. *Mol. Cell 12*, 1591–1598.

(100) Zhang, K., Mosch, K., Fischle, W., and Grewal, S. I. (2008) Roles of the Clr4 methyltransferase complex in nucleation, spreading and maintenance of heterochromatin. *Nat. Struct. Mol. Biol. 15*, 381–388.

(101) Yoon, K. A., Hwangbo, B., Kim, I. J., Park, S., Kim, H. S., Kee, H. J., Lee, J. E., Jang, Y. K., Park, J. G., and Lee, J. S. (2006) Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer. *Carcinogenesis 27*, 2217–2222.

(102) Lusser, A., Urwin, D. L., and Kadonaga, J. T. (2005) Distinct activities of CHD1 and ACF in ATP-dependent chromatin assembly. *Nat. Struct. Mol. Biol. 12*, 160–166.

(103) Gaspar-Maia, A., Alajem, A., Polesso, F., Sridharan, R., Mason, M. J., Heidersbach, A., Ramalho-Santos, J., McManus, M. T., Plath, K., Meshorer, E., and Ramalho-Santos, M. (2009) Chd1 regulates open chromatin and pluripotency of embryonic stem cells. *Nature 460*, 863–868.

(104) Hauk, G., McKnight, J. N., Nodelman, I. M., and Bowman, G. D. (2010) The chromodomains of the Chd1 chromatin remodeler regulate DNA access to the ATPase motor. *Mol. Cell 39*, 711–723.

(105) Osman, I., Bajorin, D. F., Sun, T. T., Zhong, H., Douglas, D., Scattergood, J., Zheng, R., Han, M., Marshall, K. W., and Liew, C. C. (2006) Novel blood biomarkers of human urinary bladder cancer. *Clin. Cancer Res. 12*, 3374–3380.

(106) Nagarajan, P., Onami, T. M., Rajagopalan, S., Kania, S., Donnell, R., and Venkatachalam, S. (2009) Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. *Oncogene 28*, 1053–1062.

(107) Tong, J. K., Hassig, C. A., Schnitzler, G. R., Kingston, R. E., and Schreiber, S. L. (1998) Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. *Nature 395*, 917–921.

(108) Xue, Y., Wong, J., Moreno, G. T., Young, M. K., Cote, J., and Wang, W. (1998) NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. *Mol. Cell 2*, 851–861.

(109) Burd, C. J., Kinyamu, H. K., Miller, F. W., and Archer, T. K. (2008) UV radiation regulates Mi-2 through protein translation and stability. *J. Biol. Chem. 283*, 34976–34982.

(110) Polo, S. E., Kaidi, A., Baskcomb, L., Galanty, Y., and Jackson, S. P. (2010) Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. *EMBO J. 29*, 3130–3139.

(111) Bagchi, A., Papazoglu, C., Wu, Y., Capurso, D., Brodt, M., Francis, D., Bredel, M., Vogel, H., and Mills, A. A. (2007) CHD5 is a tumor suppressor at human 1p36. *Cell 128*, 459–475.

(112) Lutz, T., Stoger, R., and Nieto, A. (2006) CHD6 is a DNA-dependent ATPase and localizes at nuclear sites of mRNA synthesis. *FEBS Lett. 580*, 5851–5857.

(113) Kalscheuer, V. M., Feenstra, I., Van Ravenswaaij-Arts, C. M., Smeets, D. F., Menzel, C., Ullmann, R., Musante, L., and Ropers, H. H. (2008) Disruption of the TCF4 gene in a girl with mental retardation but without the classical Pitt-Hopkins syndrome. *Am. J. Med. Genet. 146A*, 2053–2059.

(114) Vissers, L. E., van Ravenswaaij, C. M., Admiraal, R., Hurst, J. A., de Vries, B. B., Janssen, I. M., van der Vliet, W. A., Huys, E. H., de Jong, P. J., Hamel, B. C., Schoenmakers, E. F., Brunner, H. G., Veltman, J. A., and van Kessel, A. G. (2004) Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. *Nat. Genet. 36*, 955–957.

(115) Gao, X., Gordon, D., Zhang, D., Browne, R., Helms, C., Gillum, J., Weber, S., Devroy, S., Swaney, S., Dobbs, M., Morcuende, J., Sheffield, V., Lovett, M., Bowcock, A., Herring, J., and Wise, C. (2007) CHD7 gene polymorphisms are associated with susceptibility to idiopathic scoliosis. *Am. J. Hum. Genet. 80*, 957–965.

(116) Kim, H. G., Kurth, I., Lan, F., Meliciani, I., Wenzel, W., Eom, S. H., Kang, G. B., Rosenberger, G., Tekin, M., Ozata, M., Bick, D. P., Sherins, R. J., Walker, S. L., Shi, Y., Gusella, J. F., and Layman, L. C. (2008) Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. *Am. J. Hum. Genet. 83*, 511–519.

(117) Bajpai, R., Chen, D. A., Rada-Iglesias, A., Zhang, J., Xiong, Y., Helms, J., Chang, C. P., Zhao, Y., Swigut, T., and Wysocka, J. (2010) CHD7 cooperates with PBAF to control multipotent neural crest formation. *Nature 463*, 958–962.

(118) Sakamoto, I., Kishida, S., Fukui, A., Kishida, M., Yamamoto, H., Hino, S., Michiue, T., Takada, S., Asashima, M., and Kikuchi, A. (2000) A novel β-catenin-binding protein inhibits β-catenin-dependent Tcf activation and axis formation. *J. Biol. Chem. 275*, 32871–32878.

(119) Zahir, F., Firth, H. V., Baross, A., Delaney, A. D., Eydoux, P., Gibson, W. T., Langlois, S., Martin, H., Willatt, L., Marra, M. A., and Friedman, J. M. (2007) Novel deletions of 14q11.2 associated with developmental delay, cognitive impairment and similar minor anomalies in three children. *J. Med. Genet. 44*, 556–561.

(120) Nishiyama, M., Oshikawa, K., Tsukada, Y., Nakagawa, T., Iemura, S., Natsume, T., Fan, Y., Kikuchi, A., Skoultchi, A. I., and Nakayama, K. I. (2009) CHD8 suppresses p53-mediated apoptosis through histone H1 recruitment during early embryogenesis. *Nat. Cell Biol. 11*, 172–182.

(121) Rodriguez-Paredes, M., Ceballos-Chavez, M., Esteller, M., Garcia-Dominguez, M., and Reyes, J. C. (2009) The chromatin remodeling factor CHD8 interacts with elongating RNA polymerase II and controls expression of the cyclin E2 gene. *Nucleic Acids Res. 37*, 2449–2460.

(122) Shur, I., Solomon, R., and Benayahu, D. (2006) Dynamic interactions of chromatin-related mesenchymal modulator, a chromodomain helicase-DNA-binding protein, with promoters in osteoprogenitors. *Stem Cells 24*, 1288–1293.

(123) Sun, Y., Jiang, X., Xu, Y., Ayrapetov, M., Moreau, L., Whetstine, J., and Price, B. (2009) Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. *Nat. Cell Biol. 11*, 1376–1382.

(124) Sun, Y., Jiang, X., and Price, B. D. (2010) Tip60: Connecting chromatin to DNA damage signaling. *Cell Cycle 9*, 930–936.

(125) Dou, Y., Milne, T. A., Tackett, A. J., Smith, E. R., Fukuda, A., Wysocka, J., Allis, C. D., Chait, B. T., Hess, J. L., and Roeder, R. G. (2005) Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. *Cell 121*, 873–885.

(126) Gupta, A., Sharma, G. G., Young, C. S., Agarwal, M., Smith, E. R., Paull, T. T., Lucchesi, J. C., Khanna, K. K., Ludwig, T., and Pandita, T. K. (2005) Involvement of human MOF in ATM function. *Mol. Cell. Biol. 25*, 5292–5305.

(127) Smith, E. R., Cayrou, C., Huang, R., Lane, W. S., Cote, J., and Lucchesi, J. C. (2005) A human protein complex homologous to the *Drosophila* MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. *Mol. Cell. Biol. 25*, 9175–9188.

(128) Lai, A., Marcellus, R. C., Corbeil, H. B., and Branton, P. E. (1999) RBP1 induces growth arrest by repression of E2F-dependent transcription. *Oncogene 18*, 2091–2100.

(129) Fleischer, T. C., Yun, U. J., and Ayer, D. E. (2003) Identification and characterization of three new components of the mSin3A corepressor complex. *Mol. Cell. Biol. 23*, 3456–3467.

(130) Wu, M. Y., Eldin, K. W., and Beaudet, A. L. (2008) Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes. *J. Natl. Cancer Inst. 100*, 1247–1259.

(131) Pardo, P. S., Leung, J. K., Lucchesi, J. C., and Pereira-Smith, O. M. (2002) MRG15, a novel chromodomain protein, is present in two distinct multiprotein complexes involved in transcriptional activation. *J. Biol. Chem. 277*, 50860–50866.

(132) Chen, M., Tominaga, K., and Pereira-Smith, O. M. (2010) Emerging role of the MORF/MRG gene family in various biological processes, including aging. *Ann. N.Y. Acad. Sci. 1197*, 134–141.

(133) Morales, V., Regnard, C., Izzo, A., Vetter, I., and Becker, P. B. (2005) The MRG domain mediates the functional integration of MSL3 into the dosage compensation complex. *Mol. Cell. Biol. 25*, 5947–5954.

(134) Larschan, E., Alekseyenko, A. A., Gortchakov, A. A., Peng, S., Li, B., Yang, P., Workman, J. L., Park, P. J., and Kuroda, M. I. (2007) MSL complex is attracted to genes marked by H3K36 trimethylation using a sequence-independent mechanism. *Mol. Cell 28*, 121–133.

(135) Sural, T. H., Peng, S., Li, B., Workman, J. L., Park, P. J., and Kuroda, M. I. (2008) The MSL3 chromodomain directs a key targeting step for dosage compensation of the *Drosophila melanogaster* X chromosome. *Nat. Struct. Mol. Biol. 15*, 1318–1325.

(136) Andersen, C. L., Christensen, L. L., Thorsen, K., Schepeler, T., Sorensen, F. B., Verspaget, H. W., Simon, R., Kruhoffer, M., Aaltonen, L. A., Laurberg, S., and Orntoft, T. F. (2009) Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. *Br. J. Cancer 100*, 511–523.

(137) Schaniel, C., Ang, Y. S., Ratnakumar, K., Cormier, C., James, T., Bernstein, E., Lemischka, I. R., and Paddison, P. J. (2009) Smarcc1/Baf155 couples self-renewal gene repression with changes in chromatin structure in mouse embryonic stem cells. *Stem Cells 27*, 2979–2991.

(138) Remmelink, M., Mijatovic, T., Gustin, A., Mathieu, A., Rombaut, K., Kiss, R., Salmon, I., and Decaestecker, C. (2005) Identification by means of cDNA microarray analyses of gene expression modifications in squamous non-small cell lung cancers as compared to normal bronchial epithelial tissue. *Int. J. Oncol. 26*, 247–258.

(139) Lind, G. E., Skotheim, R. I., Fraga, M. F., Abeler, V. M., Esteller, M., and Lothe, R. A. (2006) Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1). *J. Pathol. 210*, 441–449.